No Data
No Data
Cyberdyne's New Medical Vital Sensor Approved, Insured in Japan
CYBERDYNE Unveils Innovative Cardiac Monitoring Device
Stocks that moved the day before part 2: Mitsubishi Logistics Next, Discharge Precision, Discharge Precision, etc.
Stock name <code> Closing Price on the 6th ⇒ Compared to the previous day Sumitomo Electric Industries <5802> 2931.0 -121.0 Mizuho Securities has downgraded its investment determination. Japan Steel Works <5631> 6232 -280, a situation has developed where the sense of reaching the upper limits is expanding temporarily. Fujikura <5803> 6122 -253, a trend is emerging where profit-taking sells are directed in the high price range. FP Partners <7388> 2285 -66, the Financial Services Agency has decided to conduct additional investigations regarding the company’s trades with life insurance companies. Peptidream <4587> 2810 -8310, the high price in October.
Stocks that moved the day before part 2: Eyes, Eurasia Travel Agency, Japan Oxygen HD, etc.
Stock name <code> 5-day closing price ⇒ change from previous day China Electrical Utilities <9504> 902.0 -34.7 Major electrical utilities stocks are generally in a sell-dominant trend. Japan Oxygen HD <4091> 4332 -135 morgan stanley MUFG Securities has lowered its target stock price. Rakuten Bank <5838> 4110 -126 Expectations for postponing the Bank of Japan's interest rate hike in December are strengthening. Kasumigaseki Capital <3498> 12390 -400 Approaching the 25-day moving average, profit-taking could be dominant. Tohoku Electrical Utilities <9506>
Mitsubishi Gas Chemical, Nanhai Electric Railway, etc.
Mitsubishi Gas Chemicals <4182> is investing 10 billion yen in digital technology to build an AI demand forecasting system.
Kaiom, Cyberdyne - etc.
Acquisition of land for Parma self-storage facility development (land in Yokohama, Kanagawa Prefecture) under cell <3461> Business partnership with Fuji Film Wako Pure Chemical, which is engaged in the manufacture and sale of Kaiom reagents, chemicals, and clinical diagnostic reagents under cell <4583> Direction to conduct comparative trials between the group using DFP-17729 and TS-1 in combination and the group using TS-1 alone for patients with pancreatic cancer after the third treatment with DFP-17729 under cell <4598> development situation of DFP-17729.
No Data